33
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk Factors for Renal Failure in Patients with Lupus Nephritis: Data from the Spanish Registry of Glomerulonephritis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus. Data from national registries based on renal biopsies are scarce. The aim of our study was to analyze the demographic characteristics, clinicopathological correlations, and risk factors associated with renal failure in patients with LN at the time of renal biopsy. Methods: We performed a cross-sectional observational study based on data from the Spanish Registry of Glomerulonephritis for the years 1994–2009. The outcome measure was the presence of renal failure (eGFR <60 ml/min/1.73 m<sup>2</sup>). We also recorded age, gender, proteinuria levels, hypertension, and histological class. Results: We collected 17,525 native renal biopsies, of which 1,648 biopsies showed LN lesions. In total, 609 patients (37%) showed renal failure at the time of renal biopsy. The univariate analysis showed that these patients were older, had higher levels of proteinuria, and a higher prevalence of hypertension than the group with eGFR ≥60 ml/min/ 1.73 m<sup>2</sup>. The histological class of LN was recorded for 566 patients, and multivariate logistic regression analysis showed that the independent risk factors for renal failure at the time of renal biopsy were age (OR 1.03; 95% CI 1.01–1.04), male gender (OR 1.94; 95% CI 1.12–3.10), hypertension (OR 3.18; 95% CI 2.16–4.67), proteinuria (OR 1.15; 95% CI 1.08–1.24), and histological classes III and IV (OR 1.82; 95% CI 1.16–2.87). Conclusions: Data from the Spanish Registry of Glomerulonephritis provide valuable information about risk factors for renal failure in patients with LN at the time of renal biopsy.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: not found
          • Article: not found

          Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

          M Hochberg (1997)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The classification of glomerulonephritis in systemic lupus erythematosus revisited.

            The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving or =50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Lupus nephritis.

                Bookmark

                Author and article information

                Journal
                NNE
                NNE
                10.1159/issn.1664-5529
                Nephron Extra
                S. Karger AG
                1664-5529
                2012
                January – December 2012
                10 October 2012
                : 2
                : 1
                : 269-277
                Affiliations
                aDepartment of Nephrology, Hospital General Universitario Ciudad Real, Ciudad Real, bDepartment of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, and cDepartment of Nephrology, Hospital Regional Universitario Carlos Haya, Málaga, Spain
                Author notes
                *Carmen Vozmediano Poyatos, Department of Nephrology, Hospital General Ciudad Real, Avenida Obispo Rafael Torija s/n, ES–13005 Ciudad Real (Spain), E-Mail cvozmedianop@gmail.com
                Article
                342719 PMC3493001 Nephron Extra 2012;2:269–277
                10.1159/000342719
                PMC3493001
                23139689
                d33fd402-8cb1-40fa-a542-16b56034e3d6
                © 2012 S. Karger AG, Basel

                Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) ( http://www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Page count
                Tables: 5, Pages: 9
                Categories
                Original Paper

                Cardiovascular Medicine,Nephrology
                Lupus nephritis,Renal failure,Demographics,Risk factors,National registry data

                Comments

                Comment on this article